Dr. Claude Gravel, PhD, is a professor at Laval University. He obtained his MSc and PhD in neurobiology from Laval University and completed his postdoctoral training at the Clinical Research Institute of Montreal and Harvard Medical School. Dr. Gravel has made significant contributions to the field of neuronal survival and models of proteinopathies. His research has focused on neurotrophic factors gene delivery as protective therapies for neurodegenerative diseases and gene transfer-mediated immunotherapy. With expertise in monoclonal antibody technologies, Dr. Gravel has been actively involved in the development and use of various viral vectors since the early 1990s. He played a pivotal role as the co-founder and director of the Molecular Tools Platform at CERVO from 2007 to 2016, now a pan-Canadian platform supported by multiple provincial and federal agencies.